Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) FCF Margin (2018 - 2025)

Cue Biopharma (CUE) has disclosed FCF Margin for 8 consecutive years, with 11.33% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 56164.0% to 11.33% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 145.53% through Dec 2025, up 24636.0% year-over-year, with the annual reading at 79.6% for FY2025, 31229.0% up from the prior year.
  • FCF Margin hit 11.33% in Q4 2025 for Cue Biopharma, up from 419.92% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 11.33% in Q4 2025 to a low of 49665.38% in Q2 2022.
  • Historically, FCF Margin has averaged 4068.52% across 5 years, with a median of 573.0% in 2024.
  • Biggest five-year swings in FCF Margin: tumbled -4929948bps in 2022 and later skyrocketed 4891495bps in 2023.
  • Year by year, FCF Margin stood at 128.96% in 2021, then tumbled by -5300bps to 6963.58% in 2022, then surged by 91bps to 601.76% in 2023, then grew by 5bps to 572.97% in 2024, then surged by 98bps to 11.33% in 2025.
  • Business Quant data shows FCF Margin for CUE at 11.33% in Q4 2025, 419.92% in Q3 2025, and 116.52% in Q2 2025.